EVENING SPECIALTY CONFERENCE. Gynecological Pathology

Similar documents
Outline. Workup for metastatic breast cancer. Metastatic breast cancer

Ovarian mucinous lesions. Ovarian mucinous lesions: Common diagnostic dilemmas. Ovarian mucinous lesions: problematic issues

Today s Topics. Tumors of the Peritoneum in Women

PRIMARY SEROUS CARCINOMA OF PERITONEUM: A CASE REPORT

Case of the. Month October, 2012

Frequently Asked Questions About Ovarian Cancer

Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain

Kate O Hanlan, M. D. F. A. C. O. G., F. A. C. S.

Ovarian tumors Ancillary methods

Cytopathology Case Presentation #8

Carcinosarcoma of the Ovary

Protocol for the Examination of Specimens From Patients With Tumors of the Peritoneum

3 Summary of clinical applications and limitations of measurements

Common Cancers & Hereditary Syndromes

How To Treat A Uterine Sarcoma

TUMORS OF THE TESTICULAR ADNEXA and SPERMATIC CORD

Ovarian Cancer: A Case Report

Sentinel Lymph Node Mapping for Endometrial Cancer. Locke Uppendahl, MD Grand Rounds

Ovarian cysts Diagnosis and Management

Ovarian Cancer. in Georgia, Georgia Department of Human Resources Division of Public Health

Progress and Prospects in Ovarian Cancer Screening and Prevention

The Adnexal Mass and Early Ovarian Cancer

Ovarian Cysts Made Simple Michael East. Oxford Clinic

PROTOCOL OF THE RITA DATA QUALITY STUDY

Effusions: Mesothelioma and Metastatic Cancers

Why would you need a hysterectomy?

Surgical Staging of Endometrial Cancer

WHAT S WRONG WITH MY GALL BLADDER? GALL BLADDER POLYPS

Fallopian Tube Cancer

Understanding your pathology report

Practical Effusion Cytology

OBJECTIVES By the end of this segment, the community participant will be able to:

Multiple Primary and Histology Site Specific Coding Rules KIDNEY. FLORIDA CANCER DATA SYSTEM MPH Kidney Site Specific Coding Rules

Immunostain Update: Diagnosis of Metastatic Breast Carcinoma, Emphasizing the Distinction from Gynecologic Cancers

Protocol applies to all primary borderline and malignant epithelial tumors, and malignant mesothelial neoplasms of the peritoneum.

Ovarian cancer. A guide for journalists on ovarian cancer and its treatment

ProSono Copyright Ovarian Pathology

- Slide Seminar - Endocrine pathology in non-endocrine organs. Case 11. Stefano La Rosa, Gioacchino D Ambrosio, Fausto Sessa

Tumour Markers. What are Tumour Markers? How Are Tumour Markers Used?

Immunohistochemical differentiation of metastatic tumours

Seattle. Case Presentations. Case year old female with a history of breast cancer 12 years ago. Now presents with a pleural effusion.

Challenges in gastric, appendiceal and rectal NETs Leuven,

Leah Jutzi MD, on behalf of OvCaRe

MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY

MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY

Polyps. Hyperplasias. CAP 2011: Course AP104. The High Risk Benign Endometrium. Mutter and Nucci 1

If you are still in your fertility years If you are past your fertility years and need surgery for a mass or for pain and have normal ovaries

General Rules SEER Summary Stage Objectives. What is Staging? 5/8/2014

Ovarian Cancer 101 Jessica McAlpine, MD

Introduction: Tumor Swelling / new growth / mass. Two types of growth disorders: Non-Neoplastic. Secondary / adaptation due to other cause.

Immunohistochemistry on cytology specimens from pleural and peritoneal fluid

YOUR LUNG CANCER PATHOLOGY REPORT

OVARIAN CANCER IS A MAJOR CAUSE OF MORBIDITY AND MORTALITY IN WOMEN. Name of Student HTHSCI 1110 WEBER STATE UNIVERSITY.

Understanding CA 125 Levels A GUIDE FOR OVARIAN CANCER PATIENTS. foundationforwomenscancer.org

The menstrual cycle Hypophysis

Ovarian Cancer Genetic Testing: Why, When, How?

COLORECTAL CANCER SCREENING

Introduction Ovarian cysts are a very common female condition. An ovarian cyst is a fluid-filled sac on an ovary in the female reproductive system.

Try out the online ROMA calculator available on the Elecsys HE4 page at cobas.com

National Coverage Determination (NCD) for Tumor Antigen by Immunoassay - CA 125 (190.28)

Something Old, Something New.

Pap smears, cytology and CCHC lab work and follow up

Cancer of the Cardia/GE Junction: Surgical Options

What is neuroendocrine cervical cancer?

Breast Cancer: from bedside and grossing room to diagnoses and beyond. Adriana Corben, M.D.

Hereditary Ovarian cancer: BRCA1 and BRCA2. Karen H. Lu MD September 22, 2013

Update on Mesothelioma

Ovarian Cancer. What is cancer?

Gynecology Abnormal Pelvic Anatomy and Physiology: Cervix. Cervix. Nabothian cysts. cervical polyps. leiomyomas. Cervical stenosis

Nicole Kounalakis, MD

Chapter 9 SUMMARIZING DISCUSSION AND FUTURE PERSPECTIVES WELMOED REITSMA

Barrett s oesophagus: specimen handling and reporting

Breast Cancer s Link to Ovarian Cancer: It s in Your Genes. foundationforwomenscancer.org

Cystic Neoplasms of the Pancreas: A multidisciplinary approach to the prevention and early detection of invasive pancreatic cancer.

Examples of good screening tests include: mammography for breast cancer screening and Pap smears for cervical cancer screening.

Understanding Your Diagnosis of Endometrial Cancer A STEP-BY-STEP GUIDE

PATHOLOGY OF THE PLEURA: Mesothelioma and mimickers Necessity of Immunohistochemistry. M. Praet

OVARIAN CYSTS. Types of Ovarian Cysts There are many types of ovarian cysts and these can be categorized into functional and nonfunctional

MALIGNANT MESOTHELIOMA: A TYPICAL PRESENTATION IN AN ATYPICAL PATIENT

GENETIC CONSIDERATIONS IN CANCER TREATMENT AND SURVIVORSHIP

NEOPLASMS C00 D49. Presented by Jan Halloran CCS

Ovarian. Leading the Charge against. Cancer

Case Number: RT (M) Potential Audiences: Intent Doctor, Oncology Special Nurse, Resident Doctor

Carbohydrate antigen 19 9 (CA 19 9) (serum, plasma)

CASE REPORT METASTATIC BREAST CANCER TO THE UTERINE CERVIX MIMICKING A GIANT CERVICAL LEIOMYOMA

Neoplasms of the LUNG and PLEURA

Amylase and Lipase Tests

BRIEF REPORTS. Introduction

MR Imaging of Peritoneal Malignancy Russell N. Low, MD

worry When to Cervical Abnormalities CME Workshop What s the situation? What are the trends? By Dianne Miller, MD, FRCSC In this article:

The percentage of women years of age who received one or more Pap tests to screen for cervical cancer.

PATOLOGIA MOLECULAR DEL CANCER GINECOLOGICO. Xavier Matias-Guiu Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLLEIDA.

Gynecology Abnormal Physiology of the ovaries. Simple Cystic Masses

EIN. (Endometrial Intraepithelial Neoplasia): Improved Criteria for diagnosing endometrial precancer. Stanley J. Robboy, MD, FCAP,

Hereditary Multifocal Breast Cancer. Farin Amersi M.D., F.A.C.S Division of Surgical Oncology Department of Surgery Cedar Sinai Medical Center

The Value of Thyroid Transcription Factor-1 in Cytologic Preparations as a Marker for Metastatic Adenocarcinoma of Lung Origin

Hereditary Breast Cancer. Nicole Kounalakis, MD Assistant Professor of Surgery University of Colorado Medical Center

Benign Ovarian Masses

National Program of Cancer Registries Education and Training Series. How to Collect High Quality Cancer Surveillance Data

Transcription:

EVENING SPECIALTY CONFERENCE Gynecological Pathology

Case 1 Bojana Djordjevic, MD University of Ottawa, The Ottawa Hospital, Ottawa, Ontario, Canada

Disclosure of Relevant Financial Relationships The USCAP requires that anyone in a position to influence or control the content of all CME activities disclose any relevant relationship(s) which they or their spouse/partner have, or have had within the past 12 months with a commercial interest(s) [or the products or services of a commercial interest] that relate to the content of this educational activity and create a conflict of interest. Complete disclosure information is maintained in the USCAP office and has been reviewed by the CME Advisory Committee. Dr. Bojana Djordjevic declares that she has no conflict(s) of interest to disclose.

History 74 year old woman Remote history of cervical adenocarcinoma treated with radiotherapy to the pelvis Now presenting with black and bloody stools Investigations: Negative upper endoscopy Failed colonoscopy but negative CT colonography 6 cm left ovarian cystic mass on MRI Ca-125=9 U/mL and CEA=1.4 µg/l

Findings at Laparotomy Left ovarian mass benign cystic appearance Right ovary unremarkable Appendix - shortened and firm No other GI tract abnormalities noted No peritoneal disease

Left ovary

Right ovary

Appendix

Appendix

Diagnosis Well differentiated adenocarcinoma of the appendix with metastases to the ovaries What about the fallopian tubes?

Right fallopian tube

Right fallopian tube

Right fallopian tube Wt-1

Right fallopian tube Pax8

Right fallopian tube CDX2

Case Discussion Case is presented to illustrate the intraepithelial pattern of fallopian tube involvement by extragenital mucinous adenocarcinoma Two recent retrospective case studies: Stewart et al. Histopathology. 2011. Rabban et al. Am J Surg Pathol. 2015.

Extragenital Metastases to the Fallopian Tube Clinical context Pelvic mass Benign conditions prolapse, ovarian cysts, hormonal breast ca suppression Primary source Colon -15%-35% Appendix 12%-30% Stomach 9%-30% Breast -15% Pancreas- 5% Bile duct - 5% NYD upper GI/ pancreatobiliary tract- 8% Tumor type Adenocarcinoma Lymphoma Neuroendocrine tumors Mesothelioma Urothelial carcinoma GIST Stewart et al. Histopathology. 2011. Rabban et al. Am J Surg Pathol. 2015.

Extragenital Metastases to the Fallopian Tube Ovarian involvement alone (without fallopian tube) is more common Fallopian tube involvement alone (without ovary) is relatively rare *All presented with peritoneal carcinomatosis Stewart et al. Histopathology. 2011. Rabban et al. Am J Surg Pathol. 2015.

Extragenital Metastases to the Fallopian Tube Gross appearance 35% of fallopian tubes with metastases appear normal Compared to only 14% of ovaries Grossing protocol considerations 46% of cases identified over a 4 year period with a grossing protocol that required complete submission of fallopian tubes Rest of the cases identified over a 19 year period Rabban et al. Am J Surg Pathol. 2015.

Extragenital Metastases to the Fallopian Tube Topography Fimbria and/or non-fimbriated portions Microanatomy Serosa (60-76%) Lumen (17-55%) Wall (54-70%) Lymphovascular space (38-45%) Mucosa (29-40%) Mucosal involvement may be the only pattern in a minority of cases (8%) Mucosal tumors favored the fimbriae (79%) Stewart et al. Histopathology. 2011. Rabban et al. Am J Surg Pathol. 2015.

Extragenital Metastases to the Fallopian Tube Microscopic features High or low grade cytology Rabban et al. Am J Surg Pathol. 2015.

Extragenital Metastases to the Fallopian Tube Microscopic features Mucosal involvement Single layer or stratified (ie. micropillae, cribriform, solid)

Extragenital Metastases to the Fallopian Tube Microscopic features Mucosal involvement Block-like replacement or comingling (Paget-like) with the native mucosa Mucinous differentiation is common intraluminal mucin or signet ring cells CDX2 Rabban et al. Am J Surg Pathol. 2015.

Extragenital Metastases to the Fallopian Tube Microscopic features Dissecting stromal mucin, particularly in association with appendiceal primaries

Extragenital Metastases to the Fallopian Tube Potential mechanisms of metastatic tumor spread to the fallopian tube Direct extension Lymphovascular spread Transperitoneal/transtubal spread Stewart et al. Histopathology. 2011. Rabban et al. Am J Surg Pathol. 2015.

Fallopian tube involvement by extragenital metastases......may be more common than we thought but is under-recognized because:...is rare, particularly when: 1. FT is the only site 2. There is intramucosal involvement only? 1. FTs are not collected from the majority of patients with extragenital malignancies (ie. without an associated pelvic mass) 2. In cases of a pelvic mass, in toto submission of FTs has become a recent standard 3. Intramucosal involvement might be easy to miss unless one remembers to look for it (esp. if ovary is involved)

Why is this phenomenon relevant to every day practice? Prophylactic bilateral salpingectomy and oophorectomy in the high risk BRCA1/2 mutation carrier population- a successful ovarian cancer risk reduction strategy Salpingectomy and salpingectomy with hysterectomy also recently shown to reduce ovarian cancer risk in an unselected population Domicheck et al. Lancet Oncology. 2011. Finch et al. JAMA. 2006. Rebbeck et al. NEJM. 2002. Rutter et al. J Natl Cancer Inst. 2003. Falconer et al. J Natl Cancer nst. 2015.

Why is this phenomenon relevant to every day practice? United States and Canadian societies of gynecologic oncology now recommend that salpingectomies accompany hysterectomies for benign indications Ovaries (with normal appearance on intraoperative visualization) will be left in the patient The fallopian tubes become the only organ in which diagnosis of early extragenital metastases may be made Pathologist awareness of subtle patterns of involvement (ie. mucosal) is important Careful gross examination, impact on grossing protocol Walker et al. Cancer. 2015. SGO 2011 statement : https://g-o-c.org/wp-content/uploads/2015/01/gocstmt_2011sep_salpovca_en.pdf Medeiros et al. Am J Surg Pathol. 2006.

Why is this phenomenon relevant to every day practice? AUDIENCE POLL What is the section submission protocol for fallopian tubes at your institution in cases of hysterectomy for benign indications (fibroids, adenomyosis, uterine prolapse)? Entire fallopian tube in toto Fimbriated end in toto Representative sections

Differential Diagnoses - mucosal only lesions Metaplastic changes in fallopian tube epithelium Secretory Transitional Endometrioid Mucinous Eosinophilic Pregnancy-related Mehrad et al. Adv Anat Pathol.2010.

Differential Diagnoses - mucosal only lesions Mucinous metaplasia Patient with ruptured diverticulum and peritonitis. Normal appendix. Inflammation Variety of metaplasia types Panneth cell, goblet, pyloric Case contributed by Dr. Z Eslami

Differential Diagnoses - mucosal only lesions Mucinous metaplasia Patient with ruptured diverticulum and peritonitis. Normal appendix. Immunophenotype in transition Mullerian markers are lost and intestinal markers are acquired to a different extent across different epithelial regions NOT a perfect IHC mirror image CDX2 Pax8 Consider the pattern of expression and the overall histological appearance

Differential Diagnoses - mucosal only lesions Pre-neoplastic and neoplastic fallopian tube lesions Secretory cell outgrowths Secretory tubal intraepithelial lesions Serous tubal carcinoma in situ our case Quick et al. Mod Path.2011. Vang et al. Int J Gynecol Pathol. 2013.

Differential Diagnoses - mucosal only lesions Pre-neoplastic and neoplastic fallopian tube lesions Immunohistochemistry pitfalls Beware of the elevated Ki-67 index and aberrant p53 expression in high grade lesions that resemble serous carcinoma Pax 8, Wt-1 and estrogen receptor to confirm fallopian tube origin When Pax 8 is positive but Wt-1 and/or estrogen receptor are not... Fallopian tube mucosal involvement by uterine serous carcinoma Typically Wt-1 negative, estrogen receptor staining variable Singh et al. Histopathol. 2015. Tang et al. Int J Gynecol Pathol.2012. Nofech-Mozes et al. Mod Path.2008. Euscher et al. Am J Surg Path. 2005. Akushi et al. Int J Gynecol Pathol.2010.

Fallopian tube Wt-1

Endometrium Wt-1

Summary Prophylactic salpingectomies in low risk patients are on the rise When ovaries are not present in the specimen, fallopian tubes may be the only organ in which diagnosis of extragenital disease may be made (or strongly suspected) Trigger further patient evaluation Extragenital metastases to the fallopian tube may not be grossly visible in many cases - impact on grossing protocols Patterns of fallopian tube involvement Mucosal only pattern may be difficult to recognize Remember the differential diagnoses Beware of pitfalls with use of immunohistochemistry

Thank you